Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00

Stoke Therapeutics (NASDAQ:STOK) had its target price lifted by investment analysts at HC Wainwright from $35.00 to $50.00 in a report released on Monday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 46.41% from the company’s previous close.

STOK has been the subject of a number of other reports. Wedbush lifted their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday, December 8th. Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and a consensus price target of $32.88.

Stoke Therapeutics Trading Up 5.4%

Shares of NASDAQ STOK opened at $34.15 on Monday. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 52.37 and a beta of 1.14. The business has a 50 day simple moving average of $29.85 and a 200-day simple moving average of $20.79. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million for the quarter, compared to analyst estimates of $6.06 million. As a group, equities analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 42,461 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $25.09, for a total transaction of $1,065,346.49. Following the completion of the sale, the director directly owned 49,124 shares in the company, valued at approximately $1,232,521.16. This trade represents a 46.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 10,000 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total value of $250,700.00. Following the sale, the general counsel owned 11,831 shares of the company’s stock, valued at $296,603.17. This trade represents a 45.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 182,166 shares of company stock valued at $5,136,957 in the last three months. 9.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $41,000. BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the period. Strs Ohio purchased a new position in Stoke Therapeutics during the 3rd quarter worth approximately $150,000. Finally, Osaic Holdings Inc. boosted its position in shares of Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.